Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus cyclosporine for steroid-resistant nephrotic syndrome in children
IRCT20240614062128N1Phase 2Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in nephrosis comparing Rituximab with Cyclosporine (2 arms). Primary endpoints: Age, Treatment effectiveness and 2 more. Started Aug 2024; status: completed.
02
Drugs
rituximabcyclosporine
03
Conditions
nephrosis
Beyond the preview
Go deeper on IRCT20240614062128N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240614062128N1.